Coagulopathy and blood component transfusion in trauma

被引:201
作者
Spahn, DR
Rossaint, R
机构
[1] Univ Lausanne Hosp, CHUV, Dept Anaesthesiol, CH-1011 Lausanne, Switzerland
[2] Rhein Westfal TH Aachen, Univ Hosp, Dept Anaesthesiol, D-5100 Aachen, Germany
关键词
blood; haemostasis; transfusion; complications; bleeding; coagulopathy; injury; trauma;
D O I
10.1093/bja/aei169
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Trauma is a serious global health problem, accounting for approximately one in 10 deaths worldwide. Uncontrollable bleeding accounts for 39% of trauma-related deaths and is the leading cause of potentially preventable death in patients with major trauma. While bleeding from vascular injury can usually be repaired surgically, coagulopathy-related bleeding is often more difficult to manage and may also mask the site of vascular injury. The causes of coagulopathy in patients with severe trauma are multifactorial, including consumption and dilution of platelets and coagulation factors, as well as dysfunction of platelets and the coagulation system. The interplay between hypothermia, acidosis and progressive coagulopathy, referred to as the 'lethal triad', often results in exsanguination. Current management of coagulopathy-related bleeding is based on blood component replacement therapy. However, there is a limit on the level of haemostasis that can be restored by replacement therapy. In addition, there is evidence that transfusion of red blood cells immediately after injury increases the incidence of post-injury infection and multiple organ failure. Strategies to prevent significant coagulopathy and to control critical bleeding effectively in the presence of coagulopathy may decrease the requirement for blood transfusion, thereby improving clinical outcome of patients with major trauma.
引用
收藏
页码:130 / 139
页数:10
相关论文
共 106 条
[1]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708
[2]   Transfusion risks of yesterday and of today [J].
Allain, JP .
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2003, 10 (01) :1-5
[3]   Treating Coagulopathy in trauma patients [J].
Armand, R ;
Hess, JR .
TRANSFUSION MEDICINE REVIEWS, 2003, 17 (03) :223-231
[4]   THE VIABILITY OF STORED HUMAN PLATELETS [J].
BALDINI, M ;
COSTEA, N ;
DAMESHEK, W ;
LIMAURO, A .
BLOOD, 1960, 16 (06) :1669-1692
[5]   Immunomodulatory effects of allogeneic blood transfusions: Clinical manifestations and mechanisms [J].
Blajchman, MA .
VOX SANGUINIS, 1998, 74 :315-319
[6]  
Blajchman Morris A, 2002, Am J Ther, V9, P389, DOI 10.1097/00045391-200209000-00005
[7]  
BOFFARD KD, 2004, J TRAUMA, V57, P451
[8]   Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage [J].
Bombeli, T ;
Spahn, DR .
BRITISH JOURNAL OF ANAESTHESIA, 2004, 93 (02) :275-287
[9]   Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients [J].
Chowdhury, P ;
Saayman, AG ;
Paulus, U ;
Findlay, GP ;
Collins, PW .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :69-73
[10]   CLOTTING FACTOR LEVELS AND THE RISK OF DIFFUSE MICROVASCULAR BLEEDING IN THE MASSIVELY TRANSFUSED PATIENT [J].
CIAVARELLA, D ;
REED, RL ;
COUNTS, RB ;
BARON, L ;
PAVLIN, E ;
HEIMBACH, DM ;
CARRICO, CJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1987, 67 (03) :365-368